White Book on the Current Landscape and Future Trends of the Gut Microbiota Industry
View our Complimentary White Book
From 2022 to 2023, the FDA approved two live biotherapeutic products, marking a major breakthrough for microbiota-based drugs in clinical treatment. This significantly accelerated the industrialization of microbiota therapies and holds promise to reshape disease treatment paradigms. As of April 2025, nearly 400 microbiota drug candidates are in active development worldwide, showing rapid growth. Meanwhile, the potential value of probiotics and next-generation probiotics has been increasingly recognized, drawing significant attention from both academia and industry.
Download this complimentary White Book to discover:


